Table 2 Patient characteristics
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | |
|---|---|---|---|---|---|---|---|
Age (years) | 23 | 26 | 41 | 48 | 38 | 50 | 37 |
Gender | M | M | F | F | M | F | M |
Primary acute illness | Influenza A infection | Sepsis | Influenza B and MRSA pneumonia | Sepsis post acute MI | Aspiration pneumonia | Pulmonary embolism | Type A aortic dissection |
Secondary acute illness | Cardiac arrest due to pericardial effusion | Cardiac arrest | Sepsis and cardiogenic shock | Drug overdose (calcium channel blocker and beta blocker) | Multi-organ failure | Poly-microbial sepsis | |
Confounding factors | None | Idiopathic dysautonomy and mast cell activation syndrome | Obesity | HIV positive | Obesity | Recent craniotomy for meningioma | Large RV and LV infarct |
Type of ECMO | VA ECMO | VA ECMO | VA ECMO | VV ECMO | VV ECMO | VA ECMO | VA ECMO |
Vasopressor support *pre-Ang II administration | Norepinephrine 0.4 Vasopressin 4 Epinephrine 0.07 | Norepinephrine 1 Vasopressin 6 Epinephrine 0.3 | Epinephrine 0.18 Vasopressin 2 | Norepinephrine 0.59 | Norepinephrine 1.36 Vasopressin 2.4 | Norepinephrine 0.2 Vasopressin 5 Milrinone 0.25 Epinephrine 0.05 | Norepinephrine 0.1 Vasopressin 4 Epinephrine 0.02 |
MAP at initiation of Ang II [mmHg] | Missing | 57 | 76 | 70 | 63 | 59 | 59 |
Dose of Ang II [ng/kg/min] | Missing | Missing | 20 | 20 | 40 | 20 | 20 |
Duration of Ang II | 7 days | 46 h | 50 h | 27.5 h | 80 h | ||
Time to cessation of all vasopressors after initiation of Ang II | Missing | 48 h | Missing | 16 h | 6 days | 8 days | NA |
Adverse events during Ang II infusion | None | None | Reversible digital ischemia | None | None | None | Bowel ischemia |
Patient outcome | Survival | Survival | Survival | Survival | Survival | Survival | Deceased |
Duration on ECMO [days] | 17 | 5 | 119 | 4 | 9 | 9 | 14 |
Length of stay in ICU [days] | 176 | 30 | 128 | 21 | 22 | 13 | 14 |